Futura Medical plc (FAMDF) Stock
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Futura Medical plc
Futura Medical plc is a pharmaceutical company that formulates and brings to market healthcare solutions and medicines for the consumer sector, primarily concentrating on sexual well-being and managing discomfort. Their flagship product, MED3000, is a topical gel specifically developed to address erectile dysfunction. The company's pipeline also encompasses a range of pain relief treatments, featuring TPR100, a topical diclofenac gel; CBD100, a topical cannabidiol preparation; and TIB200, a topical ibuprofen gel. Established in 2001, Futura Medical plc operates from its headquarters located in Guildford, United Kingdom.
Futura Medical plc (FAMDF) stock trades at $0.00 with a market capitalization of $712597. The stock is valued at a price-to-earnings (P/E) ratio of -0.15, price-to-book of 0.31, price-to-sales of 0.72. Over the past 52 weeks the stock has ranged between $0.00 and $0.20, and currently trades 100.0% below its 52-week high.
On profitability, Futura Medical plc generates a return on equity (ROE) of -154.16%, return on capital employed of -185.50%, an operating margin of -342.88%, a net profit margin of -450.00%.
Official website: www.futuramedical.com